标题
Targeting RTK Signaling Pathways in Cancer
作者
关键词
-
出版物
Cancers
Volume 7, Issue 3, Pages 1758-1784
出版商
MDPI AG
发表日期
2015-09-03
DOI
10.3390/cancers7030860
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage
- (2015) Xuening Wang et al. EXPERIMENTAL CELL RESEARCH
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
- (2014) Ekta Agarwal et al. BMC CANCER
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
- (2013) D W Bowles et al. BRITISH JOURNAL OF CANCER
- Molecular and cellular pathogenesis of melanoma initiation and progression
- (2013) Tarik Regad CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
- (2013) R. M. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
- (2013) V Munugalavadla et al. ONCOGENE
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
- (2012) Ted Underiner et al. Anti-Cancer Agents in Medicinal Chemistry
- ERK5 and its role in tumour development: Figure 1
- (2012) Pamela A. Lochhead et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
- (2012) Clare Davies et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Mechanisms of FGFR-mediated carcinogenesis
- (2012) Imran Ahmad et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- mTOR inhibitors in cancer therapy
- (2012) Yekaterina Y. Zaytseva et al. CANCER LETTERS
- Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
- (2012) Paul G Richardson et al. Expert Opinion on Drug Metabolism & Toxicology
- Therapeutic targeting of c-KIT in cancer
- (2012) Leonie K Ashman et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
- (2012) Johan Lennartsson et al. PHYSIOLOGICAL REVIEWS
- PI3K-PKB/Akt Pathway
- (2012) B. A. Hemmings et al. Cold Spring Harbor Perspectives in Biology
- MAP Kinase Pathways
- (2012) D. K. Morrison Cold Spring Harbor Perspectives in Biology
- Blocking the mTOR pathway: a drug discovery perspective
- (2011) Carlos Garcia-Echeverria BIOCHEMICAL SOCIETY TRANSACTIONS
- Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
- (2011) Kenji Takeuchi et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Mutant BRAF Melanomas—Dependence and Resistance
- (2011) Poulikos I. Poulikakos et al. CANCER CELL
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
- (2011) C. Cauchi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Breast Cancer-Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
- (2011) S. Previdi et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
- (2011) S. V. Bhagwat et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and functions of p38 MAPK signalling
- (2010) Ana Cuadrado et al. BIOCHEMICAL JOURNAL
- New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases
- (2010) F. Toffalini et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- 8p11 myeloproliferative syndrome: a review
- (2010) Courtney C. Jackson et al. HUMAN PATHOLOGY
- Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase
- (2009) M. Ren et al. BLOOD
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Molecular determinants of tumor recurrence in the urinary bladder
- (2009) Liang Cheng et al. Future Oncology
- Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma
- (2009) Helena Nord et al. INTERNATIONAL JOURNAL OF CANCER
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
- (2009) K.A. Hahn et al. JOURNAL OF VETERINARY INTERNAL MEDICINE
- FGFR3 mutations in prostate cancer: association with low-grade tumors
- (2009) Silvia Hernández et al. MODERN PATHOLOGY
- SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
- (2009) S. G. Buchanan et al. MOLECULAR CANCER THERAPEUTICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip
- (2009) Annie Chou et al. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
- De-regulated FGF receptors as therapeutic targets in cancer
- (2009) Victoria Knights et al. PHARMACOLOGY & THERAPEUTICS
- Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
- (2008) M S Kim et al. BRITISH JOURNAL OF CANCER
- A novel AKT3 mutation in melanoma tumours and cell lines
- (2008) M A Davies et al. BRITISH JOURNAL OF CANCER
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
- (2008) N. Rhodes et al. CANCER RESEARCH
- Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer
- (2008) I. Bernard-Pierrot et al. CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation
- (2008) Lijian Hui et al. JOURNAL OF CLINICAL INVESTIGATION
- Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer
- (2008) Qingshan Chang et al. JOURNAL OF HEPATOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting EGFR in Colorectal Cancer
- (2008) Wells A. Messersmith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer
- (2008) T. Boutros et al. PHARMACOLOGICAL REVIEWS
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer
- (2008) Kerstin B Meyer et al. PLOS BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now